Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism

BenzingaDec 16 08:04 ET

Express News | Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism

ReutersDec 16 08:00 ET

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Moomoo NewsDec 13 07:33 ET · Ratings

Corcept Therapeutics (CORT) Receives a Buy From Truist Financial

TipRanksDec 13 07:16 ET · Ratings

Insider Sale: Director at $CORT (CORT) Sells 2,200 Shares

Quiver QuantitativeDec 12 17:01 ET

Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes

BenzingaDec 12 16:09 ET